Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab

被引：0
|
作者：
Wu, J. [1 ]
Gilbert, M. R. [1 ]
De Groot, J. F. [1 ]
Yung, W. A. [1 ]
Puduvalli, V. K. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2024
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Prados, Michael
    Cloughesy, Timothy
    Samant, Meghna
    Fang, Liang
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Das, Asha
    Friedman, Henry S.
    [J]. NEURO-ONCOLOGY, 2011, 13 (01) : 143 - 151
  • [2] DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT
    Singleton, Kyle W.
    Johnston, Sandra K.
    Hawkins-Daarud, Andrea
    Rickertsen, Cassandra R.
    De Leon, Gustavo
    Kunkel, Lauren
    Whitmire, Scott A.
    Clark-Swanson, Kamala
    Bendok, Bernard
    Mrugala, Maciej
    Porter, Alyx
    Swanson, Kristin R.
    [J]. NEURO-ONCOLOGY, 2017, 19 : 163 - 163
  • [3] Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
    Singleton, Kyle W.
    Porter, Alyx B.
    Hu, Leland S.
    Johnston, Sandra K.
    Bond, Kamila M.
    Rickertsen, Cassandra R.
    De Leon, Gustavo
    Whitmire, Scott A.
    Clark-Swanson, Kamala R.
    Mrugala, Maciej M.
    Swanson, Kristin R.
    [J]. NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [4] REAL-WORLD ANALYSIS OF OUTCOMES OF PATIENTS RECEIVING BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA
    Chahal, Manik
    Harrison, Rebecca
    Mhurchu, Elaine Ni
    Thiessen, Brian
    [J]. NEURO-ONCOLOGY, 2022, 24 : 200 - 200
  • [5] Peritumoral Apparent Diffusion Coefficient as a Metric of Response in Patients with Recurrent Glioblastoma Multiforme Treated with Bevacizumab and Irinotecan
    Andre, J. B.
    Lu, S.
    Spearman, K.
    Raval, S. N.
    [J]. NEURORADIOLOGY JOURNAL, 2008, 21 (03): : 350 - 361
  • [6] ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
    Urup, Thomas
    Gillberg, Linn
    Michaelsen, Signe
    Christensen, Ib
    Broholm, Helle
    Lassen, Ulrik
    Groenbaek, Kirsten
    Poulsen, Hans
    [J]. NEURO-ONCOLOGY, 2018, 20 : 162 - 163
  • [7] ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
    Urup, Thomas
    Gillberg, Linn
    Kaastrup, Katja
    Lu, Maja Schuang
    Michaelsen, Signe Regner
    Larsen, Vibeke A.
    Christensen, Ib Jarle
    Broholm, Helle
    Lassen, Ulrik
    Gronbaek, Kirsten
    Poulsen, Hans Skovgaard
    [J]. NEURO-ONCOLOGY, 2019, 21 : 149 - 149
  • [8] OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
    Chamberlain, Marc C.
    Raizer, Jeffrey
    [J]. NEUROLOGY, 2010, 75 (03) : 289 - 290
  • [9] OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
    Sherman, J. H.
    Aregawi, D. G.
    Lai, A.
    Fathallah-Shaykh, H. M.
    Bierman, P. J.
    Linsky, K.
    Larner, J. M.
    Newman, S. A.
    Schiff, D.
    [J]. NEUROLOGY, 2009, 73 (22) : 1924 - 1926
  • [10] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 59 - 59
12345